---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-021850"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:15:23.296972+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Inhibikase signs $5.66M ATM equity distribution agreement with H.C. Wainwright

## Summary
- Entered into ATM equity offering agreement with H.C. Wainwright for up to $5,659,255 of common stock.
- Agent receives 3.0% commission on gross proceeds; company reimburses up to $50k initial legal fees plus $2.5k quarterly.
- Sales made under existing effective S-3 shelf registration statement (File No. 333-262551) at market prices.
- Company has no obligation to sell shares and may suspend or terminate the agreement at any time.

## SEC filing metadata
- accession: 0001193125-24-021850
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/0001193125-24-021850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/d769675d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-021850
- JSON: https://secwatch.observer/filing/0001193125-24-021850.json
- Plain text: https://secwatch.observer/filing/0001193125-24-021850.txt

## Key facts
- Material Agreements
  Inhibikase Therapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $5,659,255 (effective 2024-02-01).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: aggregate offering price of up to $5,659,255
  - Effective: 2024-02-01
  source text: On February 1, 2024, Inhibikase Therapeutics, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with H.C. Wainwright & Co., LLC, as sales agent (the “ Agent ”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, par value $0.001 per share, in an aggregate offering price of up to $5,659,255 (the “ Shares ”) through the Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/0001193125-24-021850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.